Harvard Bioscience
HBIO
55 hedge funds and large institutions have $73.8M invested in Harvard Bioscience in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
4% more funds holding
Funds holding: 53 → 55 (+2)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0.18% more ownership
Funds ownership: 6.18% → 6.36% (+0.18%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $80.6M → $73.8M (-$6.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.76M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.34M |
| 3 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$251K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$170K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.03M |
| 2 |
BlackRock
New York
|
-$216K |
| 3 |
RA
Royce & Associates
New York
|
-$204K |
| 4 |
Millennium Management
New York
|
-$111K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$106K |
HBIO Hedge Fund Activity: Q4 2017 in Review
55 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2017, worth a combined $73.8M — down 8.5% from $80.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new HBIO positions and 4 closed out — a net gain of 2 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $1.76M. The largest seller was Heartland Advisors, cutting an estimated $1.03M.
- 55 institutional investors held Harvard Bioscience (HBIO) as of Q4 2017, up from 53 in Q3 2017.
- Funds reported $73.8M of Harvard Bioscience stock for Q4 2017, down 8.5% quarter-over-quarter.
- 6 funds opened new Harvard Bioscience positions in Q4 2017 and 4 closed out, a net change of +2 holders.
- The largest Harvard Bioscience buyer in Q4 2017 was First Light Asset Management, an estimated $1.76M added.
- The largest Harvard Bioscience seller in Q4 2017 was Heartland Advisors, an estimated $1.03M sold.
Based on aggregated 13F filings for Q4 2017.